Contraception

Inclusion Criteria

-	Signed and dated informed consent
-	Chinese female subjects requesting oral contraception, including subjects who underwent abortion (medical or surgical) 
-	Planned use of combined oral contraceptives  for at least 6 cycles
-	Age:  18 to 45 years (inclusive); smokers must not be older than 35 years at the time of informed consent 
-	At least 4 weeks postpartum for women who are not breastfeeding or after a second trimester abortion

Exclusion Criteria

-	Evidence or suspicion of incomplete abortion (medical abortion subjects must have complete abortion confirmed by ultrasound [endometrial thickness ≤ 15 mm]).
-	Pregnancy or lactation
-	Menstrual disorders consistent with ovarian failure (eg, oligomenorrhea, amenorrhea, hypomenorrhea)
-	Abuse of alcohol, drugs, or medicine (eg, laxatives)
-	Inability to cooperate with the study procedures for any reason (eg, language comprehension, psychiatric illness, inability to get to the study site).
-	Any diseases or conditions that can compromise the function of body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication
-	Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
-	Any contraindication to YAZ according to the Chinese label, such as:
       -- Renal impairment
       -- Adrenal insufficiency
       -- A high risk of arterial or venous thromboembolic diseases.   Examples include subjects who are known to:
          --- Have deep vein thrombosis or pulmonary embolism, now or in the past 
          --- Have cerebrovascular disease 
          --- Have coronary artery disease 
          --- Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) 
          --- Have inherited or acquired hypercoagulopathies 
          --- Have uncontrolled hypertension 
          --- Have diabetes mellitus with vascular disease 
          --- Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 
       -- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past 
       -- Liver tumors, benign or malignant, or liver disease 
-	Hypersensitivity to any ingredient of the study drug
-	Undiagnosed abnormal genital bleeding
-	Sterilized subjects or concomitant use of other hormonal contraception, intrauterine device (IUD), or intrauterine system (IUS) during the study
-	For subjects qualifying for the moderate acne subgroup:
       -- Subjects with acne and atopy, comedonal acne or acne conglobata, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts
       -- Use of preparations that have an acne-inducing effect (eg, iodinated or bromated drugs, tuberculostatics, lithium, vitamin B1 [>1.5 mg daily], B6 [>2 mg daily], B12 [>6 µg daily], corticoids, adrenocorticotropic hormone anabolics, quinine, disulfiram, methoxypsoralene, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics)
       -- Subjects undergoing systemic acne treatment